Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + toripalimab
- Development stage
- Unknown
- Lead developer
- Li Ning
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sorafenib + toripalimab is an investigational combination therapy for cancer, specifically studied as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Sorafenib is a small molecule multikinase inhibitor that targets tumor cell proliferation and angiogenesis by inhibiting several kinases, including RAF kinases and various receptor tyrosine kinases such as VEGFR and PDGFR. Toripalimab is a humanized monoclonal antibody targeting programmed death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The combination aims to leverage the anti-proliferative/antiangiogenic effects of sorafenib with the immunomodulatory activity of toripalimab. Early clinical data suggest encouraging efficacy and tolerable toxicity in patients with advanced HCC[1][8].
- Brand names
- NexavarTuoyi
- Other names
- toripalimab-Sichuan University-hepatocellular carcinomatoripalimab plus sorafenibsorafenib plus toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + toripalimab.